DCN and Alzheimer disease: After reaching a peak in CSF-decorin levels in a + t − preclinical AD subjects, CSF-decorin levels start to decrease along with a continuous decrease in CSF-Aβ42 levels, and in a + t − MCI subjects the CSF-decorin levels are back to that of a-t-healthy subjects.